NEW YORK (GenomeWeb) — Cancer diagnostics firm Precipio said today that it expects to report a 213 percent increase in its second quarter revenues on strong demand for its pathology services.
On a preliminary basis, Precipio's revenues for the three-month period ended June 30 were $815,000 compared with $260,000 in the year-ago quarter. The firm said sales of its pathology services were the primary driver of the increase, in part reflecting the effect of its recently expanded sales team.